BIOCRYST PHARMACEUTICALS INC — Director's Dealing 2018

Nov 21, 2018

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: BIOCRYST PHARMACEUTICALS INC (BCRX)
CIK: 0000882796
Period of Report: 2018-11-19

Reporting Person: Powell Lynne (Senior VP - CCO)

Non-Derivative Transactions

Date	Security	Code	Shares	Price	A/D	Holdings After	Ownership
2018-11-19	Common Stock	M	193	$3.22	Acquired	8798	Direct
2018-11-19	Common Stock	S	193	$8.30	Disposed	8605	Direct
2018-11-20	Common Stock	M	9127	$3.22	Acquired	17732	Direct
2018-11-20	Common Stock	S	9127	$8.52	Disposed	8605	Direct
2018-11-20	Common Stock	S	6150	$8.61	Disposed	2455	Direct

Derivative Transactions

Date	Security	Exercise Price	Code	Shares	A/D	Expiration	Underlying	Ownership
2018-11-19	Emp. Stock Option (Right to Buy)	$3.22	M	193	Disposed	2026-05-23	Common Stock (193)	Direct
2018-11-20	Emp. Stock Option (Right to Buy)	$3.22	M	9127	Disposed	2026-05-23	Common Stock (9127)	Direct

Footnotes

F1: This transaction was made pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on August 13, 2018.

F2: The price in column 4 is a weighted average price. The shares were sold in multiple transactions ranging from $8.40 to $8.71. The reporting person will provide to the issuer, any security holder of the issuer, or the SEC staff, upon request, full information regarding the number of shares sold at each price within the range set forth in this footnote.

F3: The price in column 4 is a weighted average price. The shares were sold in multiple transactions ranging from $8.50 to $8.72. The reporting person will provide to the issuer, any security holder of the issuer, or the SEC staff, upon request, full information regarding the number of shares sold at each price within the range set forth in this footnote.